Bria Andrews

Bria Andrews serves as a key procurement professional within the Administration for Strategic Preparedness and Response (ASPR), supporting the agency’s mission to secure and deploy critical medical countermeasures and biomedical infrastructure for national health emergencies. She manages complex acquisitions aligned with rapid-response biodefense priorities, focusing on research and development contracts that advance diagnostic capabilities, therapeutic platforms, and scalable manufacturing technologies. Her work ensures the federal biomedical industrial base remains agile and prepared for pandemics, chemical threats, and emerging biological hazards, with a strong emphasis on innovation-driven procurement strategies that accelerate time-to-market for life-saving solutions. While specific contractor names are not publicly available, Andrews engages with a broad ecosystem of biotechnology firms, contract research organizations, and advanced manufacturing entities capable of delivering high-complexity R&D services under strict regulatory and security protocols. Her procurement approach prioritizes technical excellence, supply chain resilience, and performance-based contracting, fostering long-term partnerships with vendors possessing specialized expertise in molecular biology, biocontainment, and GMP-compliant production processes. Andrews’ contracting activity reflects a 100% non-set-aside profile, indicating a primary focus on technical capability over socioeconomic preferences. This pattern underscores the urgency and specialized nature of ASPR’s mission, where mission-critical performance and scientific rigor take precedence over traditional small business set-asides, though she may still consider qualified small businesses when they meet stringent technical requirements. Her procurement portfolio is exclusively centered on NAICS 541714—Research and Development in Biotechnology—encompassing early-stage vaccine development, nucleic acid therapeutics, biosensor technologies, and high-throughput screening platforms. She specializes in procuring cutting-edge biotech R&D services that bridge the gap between laboratory innovation and operational readiness, requiring deep domain knowledge in regulatory pathways, biosafety standards, and advanced biomanufacturing methodologies.